Image credit: Canva.
Metastatic melanoma is a type of skin cancer that has spread across other parts of the body. Renal cell carcinoma is a form of kidney cancer that starts in the lining of the small tubes in the kidney. A clinical trial led by Stephanie L. Goff, M.D., Associate Research Physician in the Surgery Branch, is researching a therapy for both types of cancer. Patients who are eligible will receive a combination drug therapy with pembrolizumab, a type of immune checkpoint inhibitor used to treat different cancers. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact the NCI Surgery Branch Immunotherapy Recruitment center at (866) 820-4505 or irc@nih.gov
Clinicaltrials.gov identifier: NCT05155033
NCI Protocol ID: 000354
Official Title: Phase II trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
